Objective To evaluate the efficacy and safety of intravitreal ranibizumab injection combined with triamcinolone acetonide (TA) for macular edema secondary to type Ⅱ optic disc vasculitis.Methods Totally 19 cases(19 eyes) with macular edema secondary to type Ⅱ optic disc vasculitis from January 2013 to December 2015 were injected ranibizumab intravitreally and triamcinolone acetonide 2 weeks later.The visual acuity,intraocular pressure,ocular fundus,OCT,FFA and related complications were observed during the 6 months follow-up period.If the macuiar edema returns during the follow-up period,the eyes would be given ranibizumab and TA again until the macular edema subsided.Results The visual acuity was 0.16 ± 0.09 and the central retinal thickness was (694.88 ± 79.06) μm before treatment.Compared with pretreatment,the visual acuity of all cases were improved in different degree except for one at 1 month,3 months and 6 months (all P ＜ 0.05).Also central retinal thickness were decreased and macular edema were subsided,there were statistical differences (all P ＜0.05).Compared with results at 1 month,the visual acuity and central retinal thickness was no significant different at 3 months and 6 months (all P ＞ 0.05).The intraocular pressure of all cases were normal throughout the follow-up period but one was increased transitorily in the first day after intravitreal rauibizumab injection.FFA examination at 1 month showed retinal hemorrhage and effusion absorbed obviously,besides,the optic disc and macular fluorescein leakage reduced significantly.The macular edema of 1 eye returned at 3 months and subsided after giving ranibizumab and TA again.The average number of injected eyes was 2.11 times.No complications associated with intravitreal injection and drugs were observed during the follow-up period.Conclusion It is effective and safe that intravitreal ranibizumab junction combined with TA for macular edema secondary to type Ⅱ optic disc vasculitis,which not only shorten the period of treatment but also reduce the times of drug injection,surgical trauma and complications.%目的 评价玻璃体内注射雷珠单抗(ranibizumab)联合曲安奈德(triamcinolone acetonide,TA)治疗Ⅱ型视盘血管炎继发黄斑水肿的临床疗效和安全性.方法 选取2013年1月至2015年12月Ⅱ型视盘血管炎继发黄斑水肿患者19例(19眼),所有患眼均行雷珠单抗玻璃体内注射,2周后行TA玻璃体内注射.术后随访6个月,观察视力、眼压、眼底表现、三维光学相干断层扫描、眼底荧光血管造影及相关并发症.随访期间若黄斑水肿复发则再次行雷珠单抗联合TA治疗,直至黄斑水肿消退.结果 治疗前患眼视力为0.16±0.09,黄斑中心凹视网膜厚度为(694.88 ±79.06) μm.治疗后1个月、3个月、6个月分别与治疗前相比,视力显著提高,黄斑中心凹视网膜厚度显著降低,差异均有统计学意义(均为P ＜0.05);治疗后3个月、6个月分别与治疗后1个月相比,视力及黄斑中心凹视网膜厚度无显著变化,差异均无统计学意义(均为P ＞0.05).除1眼在首次玻璃体内注射雷珠单抗后出现一过性眼压升高外,其余患眼随访期间眼压均在正常范围.治疗后1个月眼底荧光血管造影检查示视网膜出血、渗出明显吸收,视盘及黄斑部荧光素渗漏明显减轻.患眼平均注药次数为2.11次.随访期间均未观察到与玻璃体内注射及药物相关的并发症.结论雷珠单抗联合TA治疗Ⅱ型视盘血管炎继发性黄斑水肿具有良好的疗效及安全性,可以明显缩短治疗周期、减少药物注射次数,手术创伤小、并发症少.
展开▼
